STOCK TITAN

Corbus (CRBP) Chief Business Officer receives RSUs and 192,300 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. reported that Chief Business Officer Nishant C. Saxena received new equity awards. On May 21, 2026, he was granted 58,300 restricted stock units (RSUs) that will settle in common shares, bringing his direct common stock holdings to 61,800 shares.

The RSUs vest 25% on each of the first four anniversaries beginning May 21, 2027, with partial acceleration possible if he is terminated without cause after the first vesting date. He was also granted options for 192,300 shares of common stock at an exercise price of $11.51 per share, expiring in 2036, which vest 25% on May 21, 2027 and the remaining 75% in equal monthly installments over 36 months starting June 21, 2027.

Positive

  • None.

Negative

  • None.
Insider Saxena Nishant C
Role Chief Business Officer
Type Security Shares Price Value
Grant/Award Stock options (right to buy) 192,300 $0.00 --
Grant/Award Common Stock, par value $0.0001 per share 58,300 $0.00 --
Holdings After Transaction: Stock options (right to buy) — 192,300 shares (Direct, null); Common Stock, par value $0.0001 per share — 61,800 shares (Direct, null)
Footnotes (1)
  1. On May 21, 2026, the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on May 21, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service. This amount includes 58,300 unvested RSUs granted on May 21, 2026. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on May 21, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on June 21, 2027.
RSU grant 58,300 RSUs Granted May 21, 2026, vesting annually over four years
Post-grant common shares 61,800 shares Direct holdings after RSU grant
Option grant size 192,300 options Granted May 21, 2026 under 2024 Equity Compensation Plan
Option exercise price $11.51 per share Strike price for 192,300 stock options
Option expiration May 21, 2036 Expiration date of granted stock options
Initial option vesting 25% on May 21, 2027 First vesting tranche for stock options
restricted stock units ("RSUs") financial
"the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting financial
"25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Equity Compensation Plan financial
"The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan."
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
stock options (right to buy) financial
"Stock options (right to buy)"
exercise price financial
"conversion or exercise price of 11.5100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Saxena Nishant C

(Last)(First)(Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE

(Street)
NORWOOD MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share05/21/2026A58,300(1)A$061,800(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock options (right to buy)$11.5105/21/2026A192,300 (3)05/21/2036Common Stock192,300$0192,300D
Explanation of Responses:
1. On May 21, 2026, the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on May 21, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
2. This amount includes 58,300 unvested RSUs granted on May 21, 2026.
3. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on May 21, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on June 21, 2027.
/s/Meghan Houghton, Attorney-in-Fact for Nishant Saxena05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Corbus (CRBP) grant to its Chief Business Officer?

Corbus granted Chief Business Officer Nishant C. Saxena 58,300 restricted stock units and stock options for 192,300 shares. Both awards were made on May 21, 2026 as part of his compensation and are subject to multi-year vesting schedules.

How do the 58,300 RSUs granted to CRBP’s Nishant Saxena vest?

The 58,300 RSUs vest in four equal annual installments of 25% each, starting May 21, 2027. Each year on that date, another quarter of the RSUs vests, subject to continued service with Corbus Pharmaceuticals Holdings, Inc.

Is there accelerated vesting on CRBP’s RSUs if Nishant Saxena is terminated?

Yes. If Corbus terminates Nishant Saxena’s service without cause after the first vesting date, a prorated portion of the next tranche of RSUs will vest. The remaining unaccelerated RSUs are forfeited upon such a termination of service.

What are the key terms of the 192,300 stock options granted by CRBP?

The 192,300 stock options have an exercise price of $11.51 per share and expire on May 21, 2036. Twenty-five percent vests on May 21, 2027, with the remaining 75% vesting in equal monthly installments over 36 months beginning June 21, 2027.

How many Corbus (CRBP) common shares does Nishant Saxena hold after these awards?

Following the May 21, 2026 grant, Nishant Saxena directly holds 61,800 shares of Corbus common stock. This figure includes the 58,300 RSUs that were granted on that date and are unvested but reported in his share total.

Are the new Corbus (CRBP) equity awards to Nishant Saxena part of a plan?

Yes. The annual option award for 192,300 shares was made under Corbus Pharmaceuticals’ 2024 Equity Compensation Plan. The plan specifies the vesting structure, including the initial 25% cliff vest and subsequent 36 monthly vesting installments.